AIXCRYPTO HOLDINGS INC (AIXC)
NASDAQInformation TechnologySoftware - InfrastructureSnapshot 2026-11-04
$0.95-7.27%
Close 2026-11-03 · 1-day change
NASDAQInformation TechnologySoftware - InfrastructureSnapshot 2026-11-04
QuarterlyIQ Insights · AIXC
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(20.7) + peer(0.2*9.5) + term(0.0) → 9.15% (capped ±15.0)
in 8 days
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Provisional scorecard: fewer than 4 guided quarters in the corpus.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition On August 7, 2026, the Company issued a press release announcing its financial and operational results for the three months ended June 30, 2026, and an investor webcast that occurred on August 7, 2026 to discuss such results and update shareholders on general corporate developments. The press release and the investor presentation are attached as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K (this “Form 8-K”) and are inco…
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition On May 11, 2026, the Company issued a press release announcing its financial and operational results for the three months ended March 31, 2026, and an investor webcast that occurred on May 11, 2026 to discuss such results and update shareholders on general corporate developments. The press release and the investor presentation are attached as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K (this “Form 8-K”) and are incorpo…
Results of Operations and Financial Condition On March 24, 2026, the Company issued a press release announcing its financial and operational results for the fiscal year ended December 31, 2025, and an investor webcast that occurred on March 24, 2026 to discuss such results and update shareholders on general corporate developments. The press release and the investor presentation are attached as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K (this “Form 8-K”) and are i…
Results of Operations and Financial Condition. On August 15, 2023, Qualigen Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the quarter ended June 30, 2023. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of…
Results of Operations and Financial Condition. On August 16, 2022, Qualigen Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the quarter ended June 30, 2022. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of…
Results of Operations and Financial Condition. On May 13, 2022, Qualigen Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the quarter ended March 31, 2022. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Se…